Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 in Moderate-to-Severe Atopic Dermatitis Phase II Trial
CTR20222156Phase 2Completed
- Sponsor
- Henlius
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-611 in atopic dermatitis (AD), sponsored by Henlius. Started Aug 2022; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20222156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222156.